Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
Powles T, Chang YH, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, Cohen G, Yu EY, Lorch A, Bavle A, Moreno BH, Markensohn J, Edmondson M, Chen C, Cristescu R, Pena C, Lunceford J, Gunduz S.
Powles T, et al. Among authors: cohen g.
Nat Med. 2024 Jun 1. doi: 10.1038/s41591-024-03091-7. Online ahead of print.
Nat Med. 2024.
PMID: 38823511